Valuation: Simulations Plus

Market Cap 374M 334M 312M 283M 533M 36.24B 538M 3.74B 1.46B 18.41B 1.4B 1.37B 59.22B P/E 2026 *
46.3x
P/E 2027 * 42x
Enterprise Value 374M 334M 312M 283M 533M 36.24B 538M 3.74B 1.46B 18.41B 1.4B 1.37B 59.22B EV / Sales 2026 *
4.57x
EV / Sales 2027 * 4.36x
Free-Float
99.98%
Yield 2026 *
-
Yield 2027 * -
1 week+0.05%
Current month+0.38%
1 month+0.43%
3 months+1.26%
6 months+42.31%
Current year+1.48%
1 week 18.49
Extreme 18.49
18.5
1 month 18.4
Extreme 18.4
18.5
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
51.22
5 years 11.09
Extreme 11.09
67.59
10 years 8.1
Extreme 8.1011
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Date Insider Type Main position Quantity % Market Cap. Importance
06/10/26 Issuer sale

Chairman

-23,547 0.1169%
06/10/26 Issuer sale

Chief Financial Officer

-109,600 0.5440%
06/10/26 Issuer sale

Founder

-3,207,131 15.9190%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.05%+12.33%-57.65% 374M
+1.25%+0.24%+22.77%+32.30% 241B
+1.39%+2.48%+7.28%+0.46% 153B
+2.20%+8.18%-4.45%+43.99% 147B
+1.26%-0.26%-56.32%-18.91% 60.93B
+1.30%-0.05%+13.19%+16.75% 48.56B
+2.14%+3.01%-19.57%-16.99% 47.69B
+2.06%+1.42%+21.44%+52.91% 47.41B
+0.94%+5.10%-3.75%+34.77% 46.12B
+1.44%+1.38%+30.45%+61.46% 42.16B
Average +1.43%+0.34%+2.34%+14.91% 83.39B
Weighted average by Cap. +1.58%+0.46%+5.22%+23.80%

Financials

2026 *2027 *
Net sales 81.8M 73.04M 68.14M 61.9M 116M 7.92B 118M 818M 320M 4.03B 307M 300M 12.95B 85.76M 76.58M 71.44M 64.9M 122M 8.31B 123M 858M 335M 4.22B 322M 315M 13.57B
Net income 7.64M 6.82M 6.36M 5.78M 10.87M 739M 10.98M 76.36M 29.87M 376M 28.67M 28.04M 1.21B 9M 8.03M 7.5M 6.81M 12.81M 871M 12.94M 89.99M 35.2M 443M 33.78M 33.05M 1.42B
Net Debt - -
Projected Income Statement - Annual - Simulations Plus
Logo Simulations Plus
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
05/10/26 $18.50 0.00% 625,309
02/10/26 $18.50 +0.05% 460,260
01/10/26 $18.49 +0.33% 865,859
30/09/26 $18.43 -0.27% 332,435
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - Simulations Plus